Vascular Ultrasound Analysis Workstation

描述（由申请人提供）：血管形态的微小变化或 心血管疾病的早期阶段， 冠心病和中风。开发计算机化方法， 内皮功能的定量非侵入性评估，内膜-中膜 厚度和顺应性对于心血管疾病的早期评估是重要的。 疾病 在第一阶段，我们开发并验证了一种计算直径的方法， 测量肱动脉超声图像序列，并证明其 准确定量内皮功能的可行性。这项II期 建议扩展了第一阶段的工作，以开发一个全面的工具 早期发现动脉粥样硬化。 第二阶段的具体目标是： 1.开发实用、准确和高度自动化的算法和方法 评估血管血流介导的血管舒张、内膜中层厚度，以及 合规 2.开发血管超声分析工作站， 血管尺寸和功能的用户友好评估。 3.评价工作站的准确性和再现性， 图像数据。这将使就业人口众多，制药， 临床研究。 开发的工具将有可能确定受试者是谁， 动脉粥样硬化性闭塞性血管疾病。最终产品将 可作为软件包或集成的交钥匙计算机站提供。 拟议的商业应用： 我们希望我们第二阶段研究工作的结果将在类似的商业化， 作为第一阶段的成果。 商业化的第二阶段软件包将发现 它在心血管研究人员中用于流行病学研究、心血管 研究人员和制药行业进行药物相关试验，临床医生进行常规 通过测量内膜中层厚度评估中风风险。 我们还设想 开发的软件将被超声制造商采用，并成为 血管超声机的组成部分。

DESCRIPTION (Provided by Applicant):Small changes of vascular morphology or function are indicative of early stages of cardiovascular disease leading to coronary heart disease and stroke. Development of computerized methods for quantitative non-invasive assessment of the endothelial function, intima-media thickness, and compliance is important for early assessment of cardiovascular disease. During Phase I, we developed and validated a computerized method for diameter measurement in brachial ultrasound image sequences and demonstrated its feasibility for accurate quantitation of endothelial function. This Phase II proposal expands on the work done in Phase I to develop a comprehensive tool for early detection of atherosclerosis. The specific aims of Phase II are to: 1. Develop algorithms and methods for practical, accurate, and highly automated assessment of vascular flow-mediated vasodilation, intima-media thickness, and compliance. 2. Develop a Vascular Ultrasound Analysis Workstation that will allow user-friendly assessment of vascular dimensions and function. 3. Evaluate the accuracy and reproducibility of the workstation in standardized image data. This will allow employment in large population, pharmaceutical, and clinical studies. The developed tool will have the potential to identify subjects who are destined for atherosclerotic occlusive vascular disease. The final product will be available as a software package or an integrated turn-key computer station. PROPOSED COMMERCIAL APPLICATIONS: We expect that results of our Phase II research work will be commercialized in a similar fashion as the Phase I outcome. A commercialized Phase II software package will find its application among cardiovascular researchers for epidemiologic studies, cardiovascular researchers and pharmaceutical industry for drug-related trials, and clinicians for routine assessment of stroke risk via measurement of intima-media thickness. We also envision that developed software will be adopted by ultrasound manufacturers and become integral part of vascular ultrasound machines.